ClinicalTrials.gg
CompletedNCT01653756Updated Mar 17, 2021

A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects

A Phase 2 interventional study of IPI-145, a PI3K Inhibitor and Placebo to match IPI-145 in Asthma, sponsored by SecuraBio. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-03-17.

Sponsored by SecuraBio · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 385 studies in Asthma with a site in Germany — 20 open to participants now, 29 under way, 7 of them phase 3. Asthma · Germany.

Enrollment
258th of 338
50 · median 209
Started
2012
with 31 others
Phase 2
124 of 385
5 open now
Registered
172nd of 385
by date

Among the 385 studies in Asthma with a site in Germany, this one is the 258th largest by enrollment of the 338 interventional ones that give a count, is one of 32 that started in 2012, is one of 124 in phase 2, and was the 172nd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

20 of the 385 studies in Asthma with a site in Germany are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 385 studies in Asthma with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this study is to examine the effects of multi-dose regimens of IPI-145 on lung function in mild asthmatic subjects following allergen challenge.

Read the detailed description

This is a phase 2a, randomized, double-blind, placebo-controlled, multi-dose, 2-way cross-over study designed to examine the effect of IPI-145 on lung function and inflammatory indices in mild, allergen-reactive asthmatic subjects undergoing allergen challenge.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Allergen Challenge
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adults between 18 and 60 years of age
  • Diagnosis of asthma (mild) for at least 6 months prior to Screening
  • (FEV1) ≥70% of predicted value at Screening
  • A positive skin prick test to test allergen

Exclusion criteria

Exclusion Criteria:

  • Any prior treatment with a phosphoinositide-3-kinase (PI3K) inhibitor other than IPI-145 in a previous clinical study
  • Acute asthma exacerbations within 6 weeks prior to Screening
  • Use of any medication for the treatment of asthma other than a short-acting β2 agonist (as needed) within the 4 weeks prior to Screening
  • Participation in another clinical study within minimum of 30 days prior to study Screening
  • A positive screen result for active or latent tuberculosis
  • A history of cardiovascular disease
  • The concomitant use of acid-reducing agents and cholinesterase inhibiting medication
  • Inadequate hepatic function defined by (AST) and/or Alanine Aminotransferase (ALT) greater than 1.5 times greater limit of normal ()
  • Inadequate renal function defined by serum creatinine greater than 2.0 milligrams/dL
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
50 participants (actual)

Study arms

  • Active comparator
    IPI-145

    Capsules

    Drug: IPI-145, a PI3K Inhibitor · Drug: Placebo to match IPI-145

  • Placebo comparator
    Placebo

    Capsules

    Drug: IPI-145, a PI3K Inhibitor · Drug: Placebo to match IPI-145

Interventions

06

What researchers measure

Primary outcomes

  1. Forced Expiratory Volume in one second (FEV1)

    Time frame: Day 14

Secondary outcomes

  1. Maximum concentration (Cmax), Area Under the Curve, and terminal elimination half-life (T1/2) pre-dose and up to 12 hours post dose

    Time frame: Day 14

  2. Number of Participants with Adverse Events as a Measure of Safety

    Time frame: From signing of informed consent through 21 days following study drug administration

  3. Change in C-reactive Protein (CRP) levels

    Time frame: Screening and/or Day 1 of each treatment period

07

Study locations

4 sites
  • Investigational Site
    Berlin, Germany
  • Investigational Site
    Grosshansdorf, Germany
  • Investigational Site
    Wiesbaden, Germany
  • Investigational Site
    Harrow, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Aug 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2012
First posted
Jul 31, 2012
Start
Jul 2012
Primary completionActual
Aug 2014
CompletionActual
Sep 2014
Last update
Mar 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01653756
Lead sponsor
SecuraBio
Responsible party
Sponsor
First posted
Jul 31, 2012
Start date
Jul 2012
Primary completion
Aug 2014
Completion
Sep 2014
Last update
Mar 17, 2021

Study contacts

Hagop Youssoufian, MD
study chair · Verastem, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Duvelisib

Start the discussion